Enzo Biochem Inc. (ENZ)
Enzo Biochem Statistics
Share Statistics
Enzo Biochem has 52.4M shares outstanding. The number of shares has increased by 1.99% in one year.
Shares Outstanding | 52.4M |
Shares Change (YoY) | 1.99% |
Shares Change (QoQ) | 1.53% |
Owned by Institutions (%) | 26.26% |
Shares Floating | 37.75M |
Failed to Deliver (FTD) Shares | 293 |
FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 421.88K, so 0.81% of the outstanding shares have been sold short.
Short Interest | 421.88K |
Short % of Shares Out | 0.81% |
Short % of Float | 1.12% |
Short Ratio (days to cover) | 2.8 |
Valuation Ratios
The PE ratio is -2.23 and the forward PE ratio is -1.63. Enzo Biochem's PEG ratio is 0.04.
PE Ratio | -2.23 |
Forward PE | -1.63 |
PS Ratio | 1.82 |
Forward PS | 0.3 |
PB Ratio | 1.03 |
P/FCF Ratio | -2.16 |
PEG Ratio | 0.04 |
Enterprise Valuation
Enzo Biochem Inc. has an Enterprise Value (EV) of -2.62M.
EV / Earnings | 0.1 |
EV / Sales | -0.08 |
EV / EBITDA | 0.31 |
EV / EBIT | 0.27 |
EV / FCF | 0.1 |
Financial Position
The company has a current ratio of 2.82, with a Debt / Equity ratio of 0.06.
Current Ratio | 2.82 |
Quick Ratio | 2.55 |
Debt / Equity | 0.06 |
Total Debt / Capitalization | 5.89 |
Cash Flow / Debt | -7.48 |
Interest Coverage | -49.83 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -16.47%.
Return on Equity (ROE) | -0.46% |
Return on Assets (ROA) | -0.3% |
Return on Capital (ROIC) | -16.47% |
Revenue Per Employee | $255,256 |
Profits Per Employee | $-208,624 |
Employee Count | 125 |
Asset Turnover | 0.37 |
Inventory Turnover | 2.53 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -64.57% in the last 52 weeks. The beta is 0.77, so Enzo Biochem's price volatility has been higher than the market average.
Beta | 0.77 |
52-Week Price Change | -64.57% |
50-Day Moving Average | 0.54 |
200-Day Moving Average | 0.93 |
Relative Strength Index (RSI) | 34.93 |
Average Volume (20 Days) | 135.37K |
Income Statement
In the last 12 months, Enzo Biochem had revenue of 31.91M and earned -26.08M in profits. Earnings per share was -0.51.
Revenue | 31.91M |
Gross Profit | 14.63M |
Operating Income | -9.82M |
Net Income | -26.08M |
EBITDA | -8.35M |
EBIT | -9.82M |
Earnings Per Share (EPS) | -0.51 |
Balance Sheet
The company has 52.37M in cash and 3.51M in debt, giving a net cash position of 48.86M.
Cash & Cash Equivalents | 52.37M |
Total Debt | 3.51M |
Net Cash | 48.86M |
Retained Earnings | -294.43M |
Total Assets | 67.51M |
Working Capital | 35.04M |
Cash Flow
In the last 12 months, operating cash flow was -26.26M and capital expenditures -545K, giving a free cash flow of -26.8M.
Operating Cash Flow | -26.26M |
Capital Expenditures | -545K |
Free Cash Flow | -26.8M |
FCF Per Share | -0.53 |
Margins
Gross margin is 45.86%, with operating and profit margins of -30.77% and -81.73%.
Gross Margin | 45.86% |
Operating Margin | -30.77% |
Pretax Margin | -30.77% |
Profit Margin | -81.73% |
EBITDA Margin | -26.16% |
EBIT Margin | -30.77% |
FCF Margin | -84.01% |
Dividends & Yields
ENZ does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -113.33% |
FCF Yield | -114.69% |
Analyst Forecast
Currently there are no analyst rating for ENZ.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 21, 2004. It was a forward split with a ratio of 21:20.
Last Split Date | Oct 21, 2004 |
Split Type | forward |
Split Ratio | 21:20 |
Scores
Altman Z-Score | -4.89 |
Piotroski F-Score | 3 |